InvestorsObserver
×
News Home

Do Analysts Expect Acasti Pharma Inc (ACST) Stock to Rise After It Is Higher By 13.45% in a Month?

Monday, January 03, 2022 11:42 AM | InvestorsObserver Analysts

Mentioned in this article

Do Analysts Expect Acasti Pharma Inc (ACST) Stock to Rise After It Is Higher By 13.45% in a Month?

Wall Street is positive on Acasti Pharma Inc (ACST). On average, analysts give ACST a Strong Buy rating. The average price target is $6, which means analysts expect the stock to gain by 344.44% over the next twelve months. That average ranking earns ACST an Analyst Rating of 74, which is better than 74% of stocks based on data compiled by InvestorsObserver.

Overall Score - 5
Wall Street analysts are rating ACST a Strong Buy today. Find out what this means to you and get the rest of the rankings on ACST!

Why are Analyst Ratings Important?

Analytical research by professionals can be extremely useful when making investment decisions in the stock market. Analysts are able to observe industries in detail and learn how geographical impacts can affect a company's balance sheet. This information allows investors to make decisions ahead of the curve. InvestorsObserver combines the ratings from these analysts and proceeds to percentile rank them. This grants you the ability to compare stocks in a comprehensive fashion as oppossed to a standard buy/hold/sell rating.

What's Happening With Acasti Pharma Inc Stock Today?

Acasti Pharma Inc (ACST) stock is trading at $1.35 as of 11:42 AM on Monday, Jan 3, a rise of $0.09, or 7.22% from the previous closing price of $1.26. The stock has traded between $1.25 and $1.37 so far today. Volume today is less active than usual. So far 621,400 shares have traded compared to average volume of 2,665,159 shares. Click Here to get the full Stock Report for Acasti Pharma Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App